ERRATA CORRIGE

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell,[1] Kami J. Maddocks,[2] Eva González-Barca,[3] Wojciech Jurczak,[4] Anna Marina Liberati,[5] Sven de Vos,[6] Zsolt Nagy,[7] Aleš Obr,[8] Gianluca Gaidano,[9] Pau Abrisqueta,[10] Nagesh Kalakonda,[11] Marc André,[12] Martin Dreyling,[13] Tobias Menne,[14] Olivier Tournilhac,[15] Marinela Augustin,[16] Andreas Rosenwald,[17] Maren Dirnberger-Hertweck,[18] Johannes Weirather,[18] Sumeet Ambarkhane[18] and Gilles Salles[19°]

[1]Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany; [2]Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH, USA; [3]Department of Hematology, Institut Catalá d'Oncologia (ICO), Hospital Duran i Reynals, Universitat de Barcelona, Barcelona, Spain; [4]Maria Sklodowska–Curie National Research Institute of Oncology, Kraków, Poland; [5]Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy; [6]Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA, USA; [7]1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary; [8]Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic; [9]Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; [10]Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain; [11]Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, UK; [12]Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; [13]Department of Medicine III, LMU University Hospital, Munich, Germany; [14]Department of Haematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK; [15]Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont-Ferrand, France; [16]Department of Hematology and Oncology, Paracelcus Medical University, Klinikum Nürnberg, Nürnberg, Germany; [17]Institute of Pathology, University of Würzburg, Würzburg, Germany; [18]MorphoSys AG, Planegg, Germany and [19]Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon, France.

°Current address: Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

doi:10.3324/haematol.2021.279802

An error in the original manuscript (2020.275958) is present in the paper that appeared as Early view on July 1, 2021.

In Table 2, 'Efficacy outcomes in primary and follow-up analysis' The complete response for 'Last therapy refractory' should be 14 (40.0) and not 14 (14.0).

Correction

The corrected datum, a complete response rate of 40.0% in last-therapy-refractory patients receiving tafasitamab plus lenalidomide for relapsed/refractory diffuse large B-cell lymphoma, is shown in the Table below.

Table 2. Efficacy outcomes in the primary and follow-up analyses.

	Tafasitamab plus lenalidomide (N=80)‡		Clinically relevant subgroups (follow-up analysis)		
	Primary analysis (data cut-off: Nov 30, 2018)[8]	Follow-up analysis (data cut-off: Oct 30, 2020)	Primary refractory disease (n=15)	Rituximab-refractory disease (n=33)	Last-therapy-refractory (n=35)
Best objective response, n (%)					
Complete response	34 (42.5)	32 (40.0)	5 (33.3)	13 (39.4)	14 (40.0)
Partial response	14 (17.5)	14 (17.5)	3 (20.0)	5 (15.2)	7 (20.0)
Stable disease	11 (13.8)	13 (16.3)	2 (13.3)	4 (12.1)	3 (8.6)
Progressive disease	13 (16.3)	13 (16.3)	3 (20.0)	7 (21.2)	7 (20.0)
Not evaluable*	8 (10.0)	8 (10.0)	2 (13.3)	4 (12.1)	4 (11.4)
ORR (CR + PR), n (%) [95% CI]†	48 (60.0) [48.4-70.9]	46 (57.5) [45.9-68.5]	8 (53.3) [26.6-78.7]	18 (54.5) [36.4-71.9]	21 (60.0) [42.1-76.1]
Median DoR (IRC), months (95% CI)	21.7 (21.7-NR)	43.9 (26.1-NR)	NR (1.8-NR)	NR (5.8-NR)	NR (5.8-NR)
Median PFS (IRC), months (95% CI)	12.1 (5.7-NR)	11.6 (6.3-45.7)	5.3 (0.9-NR)	7.6 (2.7-NR)	7.6 (2.7-NR)
Median OS, months (95% CI)	NR (18.3-NR)	33.5 (18.3-NR)	13.8 (1.3-NR)	15.5 (8.6-NR)	15.5 (8.6-NR)

*Non-evaluable patients had no valid post-baseline response assessments. †Using the two-sided 95% Clopper-Pearson exact method based on a binomial distribution. ‡One patient received tafasitamab only. ORR: objective response rate; CR: complete response; PR: partial response; 95% CI: 95% confidence interval; DoR: duration of response; IRC: independent review committee; PFS: progression-free survival; OS: overall survival; NR: not reached.